Information for women with IATROGENIC Premature Ovarian Insufficiency

Patient version based on the ESHRE Guideline on management of women with Premature Ovarian Insufficiency
Introduction

This booklet is for you if:

- You have been diagnosed with premature ovarian insufficiency (POI) as a result of treatment for cancer or benign disease
- You are about to undergo treatment that could result in POI

This booklet is intended for patients, but may also be useful for their family members and caregivers

This booklet aims to:

- increase awareness of premature ovarian insufficiency
- encourage women with POI to attend their healthcare provider.
- provide women with POI with tools to discuss their options with their healthcare provider.

Content:

What is Premature Ovarian Insufficiency (POI)? .......................................................... 3
What are the symptoms of POI? .................................................................................. 4
What are the effects of POI on my health? ................................................................. 5
What are my options for treatment? ................................................................. 7
Where can I find more information or support? ..................................................... 9
About this booklet ........................................................................................................ 10
Dictionary ....................................................................................................................... 11

This booklet and the information presented are entirely based on the ESHRE Guideline on the management of women with Premature Ovarian Insufficiency. All the information and recommendations in the guideline are based on the best available evidence from research. When there is insufficient evidence from research, a group of experts have formulated recommendations based on their clinical expertise.

We have added the following symbols to explain the strength of the recommendations

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>🍃</td>
<td>Strong recommendation based on research evidence</td>
</tr>
<tr>
<td>✔️</td>
<td>Recommendation based on considered opinion of the guideline development group</td>
</tr>
</tbody>
</table>

More information is available at the last pages of this booklet. The entire guideline is available on the website of ESHRE (www.eshre.eu/guidelines)
What is Premature Ovarian Insufficiency (POI)?

Premature Ovarian Insufficiency or “POI” was first described in 1942 and since then has been described with different names and definitions. Other names often used for premature ovarian insufficiency are primary ovarian insufficiency, premature ovarian failure, gonadal dysgenesis, premature menopause, early menopause and hypergonadotropic hypogonadism.

POI is a condition where the ovaries stop functioning properly before the age of 40. The ovaries stop releasing eggs and stop producing hormones (estrogen, progesterone, testosterone).

The diagnosis of POI is made by evaluating the frequency of periods (over at least 4 months), and by measuring the hormone levels in the blood (2 measurements at least 4 weeks apart both showing elevated levels of Follicle Stimulating Hormone [FSH]).

What is iatrogenic POI?

POI can be caused by genetic factors, autoimmune diseases or, more rarely, infection. In a large proportion of women with POI, the cause is unknown (idiopathic POI). This booklet is written for women with POI resulting from treatment (chemotherapy, radiotherapy, surgery) for cancer or benign diseases. This type of POI is labelled iatrogenic POI.

Chemotherapy and radiotherapy for treatment of cancer or benign diseases may cause damage to the ovaries, leading to POI. The amount of damage depends on several factors, including the type and dose of treatment, the field of radiation and the age of the patient. It is often difficult to predict whether a woman will develop POI. Only when ovarian function does not resume a period of time after the treatment is stopped, can a woman be diagnosed with POI.

Surgery to the uterus or ovaries before the age of 40 years may lead to the development of POI. Examples of such surgery include the treatment of endometriosis or ovarian cysts, especially if needed repeatedly.

Finally, the removal of both ovaries before the age of 40 years results in POI. Removal of the ovaries (ovariectomy/oophorectomy) could be performed because of high risk of developing ovarian cancer, e.g. in women carrying a mutation in the BRCA gene.

The possibility of POI being a consequence of a medical or surgical intervention should be discussed with you as part of the consenting process for that treatment. Ask your doctor to explain!

If you are scheduled to undergo treatment for cancer or benign diseases that could result in POI, your doctor should discuss this with you before starting treatment.

The topics that should be discussed are:
- your risk of developing POI,
- your options for prevention of POI, and
- your options for fertility preservation prior to surgery, if applicable.
What are the symptoms of POI?

Women with POI will often stop menstruating (called amenorrhea), or they will have less frequent periods (called oligomenorrhea). You may also experience a range of symptoms resulting from a reduction in estrogen, or you may not have any symptoms.

Possible symptoms caused by low estrogen are hot flushes, night sweats, vaginal dryness, pain during sexual intercourse, sleep disturbances, mood changes, poor concentration, stiffness, low libido, dry eyes, change in urinary frequency, and lack of energy.

5 Tips to manage your symptoms

1. Keep a healthy lifestyle, including
   - A balanced diet and a healthy weight
   - Regular (weight-bearing) exercise
   - Limited alcohol

   Although the evidence is limited, a healthy lifestyle is believed to have a beneficial effect on general health and on the impact of POI on your body. Particularly, a healthy lifestyle can reduce the impact of POI on bone and heart health, and therefore it is recommended that you try to be healthy.

2. Stop smoking

   There are no studies showing that stopping smoking has a beneficial effect on the symptoms of POI. However, quitting smoking will benefit your general health and may have positive effects on POI.

3. Get an annual appointment with your doctor.

   Cardiovascular risk should be assessed in women diagnosed with POI, at least blood pressure, weight and smoking status. Women with POI using HRT should have a clinical review annually.

4. Comply with your therapy

   Unless you have a history of breast cancer, HRT is safe and helpful to relieve symptoms and prevent problems with heart disease, or bone health later in life. Compliance with treatment is essential.

5. Discuss any symptoms you experience with your doctor. S/he can inform you of treatment options, or advice on how to deal with these symptoms. Never hesitate to mention questions or concerns

If you feel the diagnosis of POI has a major impact on your well being, your doctor can offer you psychological support. Similarly, treatments are available for the impact of POI on your sex life.
What are the effects of POI on my health?

Being diagnosed with POI may be a life changing experience. When the diagnosis of POI results from treatment for cancer or benign diseases, you may feel overwhelmed and lost.

POI can have an impact on different parts of your body.

1. Infertility

As POI is a condition where the ovaries stop functioning properly before the age of 40, the chance of conceiving naturally is significantly reduced.

If you have POI due to damage to the ovaries from chemotherapy or radiotherapy, you may have difficulties getting pregnant naturally. However, there may be a small chance of spontaneous pregnancy, so your doctor should discuss the need for contraception with you.

If you had both ovaries removed during surgery, you are no longer able to get pregnant spontaneously.

In vitro fertilization (IVF) is an option to get pregnant after POI if you had the opportunity to store oocytes (egg cells) or ovarian tissue before receiving chemotherapy, radiotherapy or surgery.

If you did not have the opportunity of fertility preservation before treatment (freezing of oocytes or ovarian tissue), you may still be able to get pregnant through oocyte donation (egg donation).

If you consider oocyte donation from your sister you should be aware that this carries a higher risk of an insufficient number of eggs maturing in your sister’s ovaries during treatment leading to cancellation of the cycle.

Depending on your previous treatment (chemotherapy or radiotherapy), you may be at increased risk for complications during pregnancy. To prevent these complications, your doctor may perform some additional test before pregnancy, and if needed refer you to a cardiologist. Also, your doctor may monitor you more closely during pregnancy.
2. Sex life

You may experience vaginal dryness, reduced libido, and pain during intercourse due to POI. These symptoms could have significant impact on your sex life.

The combination of infertility, menopausal symptoms, lack of energy and the impact of having cancer or a benign disease may result in a significant impact on your sex life and the relationship with your partner.

Your doctor should discuss the impact on your sex life with you, and can recommend the use of hormone replacement therapy, estrogen creams, testosterone or lubricants.

It may also be helpful to discuss your feelings and concerns with your partner.

3. Bone, heart and brain

Hormones, especially estrogen, are important for the normal functioning of a (young) woman’s body. Reduced estrogen levels do not only result in menopausal symptoms, but can also affect the health of your bones, heart and brain.

- POI is associated with reduced bone mineral density; you may be at increased risk of bone fractures later in life.
- POI is associated with an increased risk of developing heart disease.
- POI may have an impact on your memory.

A healthy lifestyle (e.g. exercise, cessation of smoking, maintaining a healthy weight) can reduce the impact of POI on your bones, heart and brain.

Your doctor will monitor the health of your bones (if needed by performing a DEXA scan) and your heart (by checking your blood pressure). S/he will also prescribe hormone replacement therapy (HRT), if this is not contra-indicated for you (see also next section).
What are my options for treatment?

POI cannot be cured, but treatment can alleviate your symptoms and reduce the long term effects on your health.

1. HORMONE REPLACEMENT THERAPY (HRT)

In women with POI, the ovaries will stop producing hormones (estrogen, progesterone, testosterone), which are needed for a healthy body. HRT aims to restore the levels of these hormones in your body to a similar level as women of the same age without POI.

Hormone replacement therapy is indicated for the treatment of symptoms of low estrogen in women with POI.

HRT may have a role in the prevention of heart disease, and it may protect your bones.

Studies have shown that HRT improves the typical symptoms of POI (hot flushes, night sweats). In women with POI, HRT is safe; studies have shown that HRT in women with POI does not increase the risk of breast cancer.

Patient preference for route and method of administration of each component of HRT must be considered when prescribing, as should contraceptive needs.

The combined oral contraceptive pill may be appropriate for some women but effects on the bones are less favourable.

Your doctor should discuss the different HRT options with you to help you decide which one would be the most appropriate for you.

Your underlying condition and general health will have a significant impact on whether or not you can receive HRT and which regimen is best for you. Also, your doctor may perform some tests before prescribing HRT. The recommended treatment is as follows:

- **Migraine**: Not contraindicated – estrogen patches preferred
- **Hypertension**: Not contraindicated – estrogen patches preferred
- **History of prior venous thromboembolism (VTE) or thrombophilic disorder**: Not contraindicated – referral to a haematologist recommended before starting HRT – estrogen patches preferred
- **Obesity or overweight**: Not contraindicated – estrogen patches preferred
- **Fibroids**: Not contraindicated
- **Endometriosis**: HRT can be effective; estrogen therapy alone may cause reactivation of endometriosis. Combined HRT may reduce the risk of reactivation.
- **POI after breast cancer**: Contraindicated: HRT should not be prescribed to you.
- **POI after removal of the ovaries (e.g. for a BRCA mutation)**: You can use HRT as long as you did not have (breast) cancer.
② ANDROGEN THERAPY (testosterone)
Androgen therapy has been proposed as a treatment for the effects of POI on your sex life, bones and memory, but studies are limited and the long-term side-effects of androgen treatment are unknown.

Androgen treatment is only supported by limited data, and the long-term health effects are not clear yet. If androgen therapy is commenced, treatment effect should be evaluated after 3-6 months and should possibly be limited to 24 months.

③ LOCAL TREATMENTS (vaginal estrogen cream/pessaries, lubricants)
Some women with POI experience significant sexual problems, either uncomfortable or painful intercourse from vaginal dryness (genito-urinary symptoms), or sexual changes such as altered libido and arousal. HRT may improve these symptoms, although there are no good studies of women with POI.

Local estrogens are effective in treatment of genito-urinary symptoms. You may experience genito-urinary symptoms despite seemingly adequate systemic hormone replacement therapy (HRT). Vaginal estrogens may be given in addition to systemic HRT. Lubricants are useful for treatment of vaginal discomfort and painful sex due to vaginal dryness whether or not HRT is being used.

④ COMPLEMENTARY TREATMENTS
Several alternative and complementary treatments have been advocated to reduce symptoms of low estrogen, including phyto-estrogens (soy and red clover), black cohosh, evening primrose oil, dong quai, panax ginseng, wild yam and vitamin E. For some of these treatments, studies have shown a small reduction in symptoms. However, these studies are small and of low scientific quality. In addition, they do not provide information on whether the treatment is safe.

For most alternative and complementary treatments, evidence on efficacy is limited and data on safety are lacking. Women with a history of estrogen-dependent cancer should use phyto-estrogens (soy and red clover) with caution as they may not be safe.
Where can I find more information or support?

More detailed information on each of the topics in this booklet can be found in the clinicians’ edition of the guideline on the ESHRE website (www.eshre.eu/guidelines).

For more detailed information or support, you can contact your doctor or a patient organisation.

In some European countries, there are patient organisations specifically for women with Premature Ovarian Insufficiency, while in other countries, these patients could find information and support through national patient organisations for infertility.

The Daisy Network is a support group for women suffering with Premature Ovarian Insufficiency (POI). They are a registered charity in the UK but have members from all over the world. Their aim is to provide support, information and a friendly network of people for their members. You can find more information at their website https://www.daisynetwork.org.uk/

For contact details of national patient organisations for infertility, you can ask your doctor, or contact Fertility Europe (www.fertilityeurope.eu)
About this booklet

This booklet aims to involve patients in healthcare improvement, either by learning about the current standard of care, or by enabling patients to make informed decisions on their health, supported by the best available evidence.

How this booklet was developed

This booklet was written by Dr Nathalie Vermeulen (methodological expert), and revised by Jane Bartlett (patient representative) and Dr Lisa Webber (gynecologist and chair of the Guideline Development Group). All the information provided is based on the recommendations in the ESHRE guideline: management of women with Premature Ovarian Insufficiency (POI).

Who developed the ESHRE guideline?

The ESHRE guideline: management of women with Premature Ovarian Insufficiency (POI), was developed by a multidisciplinary guideline development group including gynaecologists and endocrinologists, but also experts in bone health, cardiology, psychology and neurology, a literature methodology expert and a patient representative.

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lisa Webber</td>
<td>University College London Hospital (UK)</td>
</tr>
<tr>
<td>Melanie Davies</td>
<td>University College London Hospital (UK)</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>University of Edinburgh (UK)</td>
</tr>
<tr>
<td>Didi Braat</td>
<td>Radboudumc Nijmegen (The Netherlands)</td>
</tr>
<tr>
<td>Beth Cartwright</td>
<td>ST5 Obstetrics and Gynaecology trainee London KSS (UK)</td>
</tr>
<tr>
<td>Renata Cifkova</td>
<td>Center for Cardiovascular Prevention, Charles University in Prague, First Faculty of Medicine and Thomayer Hospital (Prague, Czech Republic)</td>
</tr>
<tr>
<td>Sabine de Muinck Keizer-Schrama</td>
<td>Erasmus University Medical Center- Sophia Children's Hospital Rotterdam (The Netherlands)</td>
</tr>
<tr>
<td>Eef Hogervorst</td>
<td>Applied Cognitive Research (SSEHS) (UK)</td>
</tr>
<tr>
<td>Femi Janse</td>
<td>UMC Utrecht (The Netherlands)</td>
</tr>
<tr>
<td>Lih-Mei Liao</td>
<td>University College London Hospital (UK)</td>
</tr>
<tr>
<td>Veljko Vlaisavljevic</td>
<td>University Medical Centre, Dept. Reproductive Medicine (Slovenia)</td>
</tr>
<tr>
<td>Carola Zillikens</td>
<td>Erasmus MC Rotterdam (The Netherlands)</td>
</tr>
<tr>
<td>Jane Bartlett</td>
<td>The Daisy Network (UK)</td>
</tr>
<tr>
<td>Nathalie Vermeulen</td>
<td>European Society of Human Reproduction and Embryology</td>
</tr>
</tbody>
</table>
Dictionary

**Assisted reproductive technology (ART):** The name for treatments that enable people to conceive by means other than sexual intercourse. Assisted reproduction techniques include intra-uterine insemination (IUI), in vitro fertilisation (IVF), intracytoplasmic sperm injection (ICSI), donor insemination and egg donation.

**Controlled ovarian stimulation (COS):** For ART: pharmacologic treatment in which women are stimulated to induce the development of multiple ovarian follicles to obtain multiple oocytes at follicular aspiration.

**Dysmenorrhea:** Severe pain in the lower abdomen or back, sometimes together with nausea, depression and headache, directly before and/or during menstruation.

**Dyspareunia:** Recurrent or persistent genital pain directly before, during or shortly after coitus (sexual intercourse).

**Embryo:** A fertilised egg.

**Estrogen/Oestrogen:** A female sex hormone produced by developing eggs in the ovaries, which stimulates the development of female sex characteristics.

**Hormone:** A molecule that is produced by one tissue and carried in the bloodstream to another tissue to cause a biological effect.

**In vitro fertilization (IVF):** A technique by which eggs are collected from a woman and fertilised with a man’s sperm outside the body. Usually one or two resulting embryos are then transferred to the womb. If one of them attaches successfully, it results in a pregnancy.

**Infertility:** the state of being not fertile and unable to become pregnant. Clinical definition of infertility: A disease of the reproductive system defined by the failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse.

**Intra-uterine insemination (IUI):** A technique to place sperm into a woman’s womb through the cervix.

**Intracytoplasmic sperm injection (ICSI):** A variation of IVF in which a single sperm is injected into an egg.

**Medically assisted reproduction (MAR):** Reproduction brought about through ovulation induction, controlled ovarian stimulation, ovulation triggering, ART procedures, and intrauterine, intracervical, and intravaginal insemination with semen of husband/partner or donor.

**Menstruation:** The monthly period or bloody discharge from the uterus; it consists of blood and endometrium sloughed from the uterine lining.

**Ovary:** a paired organ in the pelvis of women containing the eggs and the site of female sex hormone production.

**Progesterone:** A hormone produced by the ovary, but only if ovulation has occurred (after the egg is released). Its action is to prepare the endometrium for implantation of the embryo.
Disclaimer

The European Society of Human Reproduction and Embryology (ESHRE) developed the current information booklet for patients based on the clinical practice guideline. The aim of clinical practice guidelines is to aid healthcare professionals in everyday clinical decision about appropriate and effective care of their patients.

This booklet is in no way intended to replace, dictate or fully define evaluation and treatment by a qualified physician. It is intended solely as an aid for patients seeking general information on issues in reproductive medicine.

ESHRE makes no warranty, express or implied, regarding the clinical practice guidelines or patient information booklets and specifically excludes any warranties of merchantability and fitness for a particular use or purpose. ESHRE shall not be liable for direct, indirect, special, incidental, or consequential damages related to the use of the information contained herein. While ESHRE makes every effort to compile accurate information and to keep it up-to-date, it cannot, however, guarantee the correctness, completeness and accuracy of the guideline or this booklet in every respect.

The information provided in this document does not constitute business, medical or other professional advice, and is subject to change.

Copyright © European Society of Human Reproduction and Embryology - All rights reserved

The content of these ESHRE guidelines has been published for personal and educational use only. No commercial use is authorised. No part of the ESHRE guidelines may be translated or reproduced in any form without prior written permission of the ESHRE communications manager.